From the Journals

Industry Insights: Advanced Breast Cancer Diagnostics

How droplet digital PCR technology is addressing key challenges in ESR1 mutation testing

  • By

  • January 15, 2026

  • 11 min

Share

The advancements in breast cancer diagnostics are significantly influenced by the emergence of targeted therapies for ESR1 mutations. These developments compel laboratories to make informed choices about testing platforms that prioritize both efficacy and economic viability. Key figures from Biodesix and Bio-Rad emphasize the challenges of ESR1 testing, including issues of accessibility and reimbursement. The transition from next-generation sequencing (NGS) to more cost-effective solutions like droplet digital PCR (ddPCR) could enhance patient access to suitable treatments, pushing forward the landscape of precision oncology.

Original Source(s)

Industry Insights: Advanced Breast Cancer Diagnostics

How droplet digital PCR technology is addressing key challenges in ESR1 mutation testing

  • January 15, 2026

  • 11 min

Related Content

Scaling Science: My Precision Medicine Accessibility Mission

Sitting Down With… Luca Quagliata, Vice President and Global Head of Medical Affairs at Thermo Fisher Scientific

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Two genetic subtypes of childhood B-cell acute lymphoblastic leukemia (B-ALL) have long been associated with inferior treatment outcomes: Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL.

  • by

  • January 29, 2026

  • 3 min
What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.

  • by

  • January 28, 2026

  • 8 min